Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hazlehurst, L. A.
Right arrow Articles by Dalton, W. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hazlehurst, L. A.
Right arrow Articles by Dalton, W. S.
Related Collections
Right arrow Neoplasia
Right arrow Apoptosis
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 15 September 2001, Vol. 98, No. 6, pp. 1897-1903

NEOPLASIA

Reduction in drug-induced DNA double-strand breaks associated with beta 1 integrin-mediated adhesion correlates with drug resistance in U937 cells

Lori A. Hazlehurst, Nikola Valkov, Lee Wisner, Jonathan A. Storey, David Boulware, Daniel M. Sullivan, and William S. Dalton

From the Department of Interdisciplinary Oncology and Clinical Investigations Program and the Biostatistical Department, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL.

We previously showed that adhesion of myeloma cells to fibronectin (FN) by means of beta 1 integrins causes resistance to certain cytotoxic drugs. The study described here found that adhesion of U937 human histiocytic lymphoma cells to FN provides a survival advantage with respect to damage induced by the topoisomerase (topo) II inhibitors mitoxantrone, doxorubicin, and etoposide. Apoptosis induced by a topo II inhibitor is thought to be initiated by DNA damage. The neutral comet assay was used to determine whether initial drug-induced DNA damage correlated with cellular-adhesion-mediated drug resistance. Cellular adhesion by means of beta 1 integrins resulted in a 40% to 60% reduction in mitoxantrone- and etoposide-induced DNA double-strand breaks. When the mechanisms regulating the initial drug-induced DNA damage were examined, a beta 1 integrin-mediated reduction in drug-induced DNA double-strand breaks was found to correlate with reduced topo II activity and decreased salt-extractable nuclear topo IIbeta protein levels. Confocal studies showed changes in the nuclear localization of topo IIbeta ; however, alterations in the nuclear-to-cytoplasmic ratio of topo IIbeta in FN-adhered cells were not significantly different. Furthermore, after a high level of salt extraction of nuclear proteins, higher levels of topo IIbeta -associated DNA binding were observed in FN-adhered cells than in cells in suspension. Together, these data suggest that topo IIbeta is more tightly bound to the nucleus of FN-adhered cells. Thus, FN adhesion by means of beta 1 integrins appears to protect U937 cells from initial drug-induced DNA damage by reducing topo II activity secondarily to alterations in the nuclear distribution of topo IIbeta .

© 2001 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Cancer Res.Home page
K. H. Shain, D. N. Yarde, M. B. Meads, M. Huang, R. Jove, L. A. Hazlehurst, and W. S. Dalton
{beta}1 Integrin Adhesion Enhances IL-6-Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation
Cancer Res., February 1, 2009; 69(3): 1009 - 1015.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. S. Becker, K. J. Kopecky, A. N. Wilks, S. Chien, J. M. Harlan, C. L. Willman, S. H. Petersdorf, D. L. Stirewalt, T. Papayannopoulou, and F. R. Appelbaum
Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia
Blood, January 22, 2009; 113(4): 866 - 874.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. B. Meads, L. A. Hazlehurst, and W. S. Dalton
The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
Clin. Cancer Res., May 1, 2008; 14(9): 2519 - 2526.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. E. Perez, N. Parquet, K. Shain, R. Nimmanapalli, M. Alsina, C. Anasetti, and W. Dalton
Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP
J. Immunol., February 1, 2008; 180(3): 1545 - 1555.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. Kobune, H. Chiba, J. Kato, K. Kato, K. Nakamura, Y. Kawano, K. Takada, R. Takimoto, T. Takayama, H. Hamada, et al.
Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism
Mol. Cancer Ther., June 1, 2007; 6(6): 1774 - 1784.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Yoshimi, S. Yamaji, A. Suzuki, W. Mishima, M. Okamura, T. Obana, C. Matsuda, Y. Miwa, S. Ohno, and Y. Ishigatsubo
The {gamma}-Parvin-Integrin-Linked Kinase Complex Is Critically Involved in Leukocyte-Substrate Interaction
J. Immunol., March 15, 2006; 176(6): 3611 - 3624.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. A. Hazlehurst, R. F. Argilagos, M. Emmons, D. Boulware, C. A. Beam, D. M. Sullivan, and W. S. Dalton
Cell Adhesion to Fibronectin (CAM-DR) Influences Acquired Mitoxantrone Resistance in U937 Cells
Cancer Res., February 15, 2006; 66(4): 2338 - 2345.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. L. Rose, H. Huang, S. F. Wray, and D. G. Hoyt
Integrin Engagement Increases Histone H3 Acetylation and Reduces Histone H1 Association with DNA in Murine Lung Endothelial Cells
Mol. Pharmacol., August 1, 2005; 68(2): 439 - 446.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
J. G. Turner, R. Engel, J. A. Derderian, R. Jove, and D. M. Sullivan
Human topoisomerase II{alpha} nuclear export is mediated by two CRM-1-dependent nuclear export signals
J. Cell Sci., June 15, 2004; 117(14): 3061 - 3071.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. A. Hazlehurst, S. A. Enkemann, C. A. Beam, R. F. Argilagos, J. Painter, K. H. Shain, S. Saporta, D. Boulware, L. Moscinski, M. Alsina, et al.
Genotypic and Phenotypic Comparisons of de Novo and Acquired Melphalan Resistance in an Isogenic Multiple Myeloma Cell Line Model
Cancer Res., November 15, 2003; 63(22): 7900 - 7906.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. Mitsiades, C. S. Mitsiades, P. G. Richardson, V. Poulaki, Y.-T. Tai, D. Chauhan, G. Fanourakis, X. Gu, C. Bailey, M. Joseph, et al.
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
Blood, March 15, 2003; 101(6): 2377 - 2380.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. H. Shain, T. H. Landowski, and W. S. Dalton
Adhesion-Mediated Intracellular Redistribution of c-Fas-Associated Death Domain-Like IL-1-Converting Enzyme-Like Inhibitory Protein-Long Confers Resistance to CD95-Induced Apoptosis in Hematopoietic Cancer Cell Lines
J. Immunol., March 1, 2002; 168(5): 2544 - 2553.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. M. Oshiro, T. H. Landowski, R. Catlett-Falcone, L. A. Hazlehurst, M. Huang, R. Jove, and W. S. Dalton
Inhibition of JAK Kinase Activity Enhances Fas-mediated Apoptosis but Reduces Cytotoxic Activity of Topoisomerase II Inhibitors in U266 Myeloma Cells
Clin. Cancer Res., December 1, 2001; 7(12): 4262 - 4271.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. H. Shain and W. S. Dalton
Cell Adhesion Is a Key Determinant in de Novo Multidrug Resistance (MDR): New Targets for the Prevention of Acquired MDR
Mol. Cancer Ther., November 1, 2001; 1(1): 69 - 78.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020